<DOC>
	<DOC>NCT02575950</DOC>
	<brief_summary>An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of LEO 43204 in adults with moderate to severe acne.</brief_summary>
	<brief_title>Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Subjects should be diagnosed with acne vulgaris of the face Fitzpatrick skin types IIII (due to lack of safety data for the investigational product in darker skin types) Disease severity and total lesion count should be similar in both TAs Disease severity grade as moderate to severe according to the investigator's global assessment (grade 34) Age 18 to 35 years incl. Male or female Female Subjects must be of either nonchildbearing potential or childbearing potential with a confirmed negative pregnancy test Subjects with nodulocystic acne, acne conglobata, acne fulminans, secondary acne (e.g. chloracne, druginduced acne) Subjects with previous history of keloid formation or postinflammatory hyperpigmentation Systemic retinoids within 12 month or systemic antibiotics within 1 month before Day 1 Topical retinoids within 3 months before Day 1 or other topical treatments and/or medicated products and cosmetics that in the opinion of the investigator may influence the subjects acne vulgaris (including soaps containing antibacterial agents such as benzoyl peroxide, keratinolytic agents such as salicylic acid, skin fresheners/astringents or aftershave products) within 1 month before Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>